导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.02% | 3344/4773 |
| 近一周 | -4.65% | 5044/5462 |
| 近一月 | -4.63% | 2604/5421 |
| 近一季 | -10.73% | 3564/5209 |
| 近半年 | -16.90% | 4130/4920 |
| 近一年 | 16.79% | 572/4366 |
| 近两年 | 104.77% | 559/2954 |
| 近三年 | 77.10% | 231/2253 |
| 成立以来 | 99.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.89% 838/4961 |
-5.46% 3580/5312 |
- - |
- - |
| 2025 | 89.95% 62/4813 |
9.50% 385/3635 |
4.64% 723/4076 |
44.77% 616/4524 |
14.51% 85/4813 |
| 2024 | 5.65% 1822/3463 |
10.49% 57/2808 |
-3.62% 1400/3014 |
10.59% 2611/3129 |
-10.30% 2978/3463 |
| 2023 | -8.24% 991/2656 |
6.92% 629/2280 |
-8.02% 1950/2385 |
-3.38% 911/2515 |
-3.42% 688/2655 |
| 2022 | -17.80% 632/2207 |
-4.85% 172/1919 |
1.50% 1470/2016 |
-14.81% 1152/2113 |
-0.08% 1559/2208 |
| 2021 | 37.71% 44/1822 |
1.70% 246/1255 |
11.11% 400/1330 |
24.17% 29/1466 |
-1.85% 1391/1822 |
| 2020 | 36.61% 390/1250 |
-14.12% 948/1028 |
10.85% 755/1067 |
9.81% 617/1164 |
30.69% 18/1184 |
| 2019 | 23.27% 631/1092 |
18.12% 643/754 |
-0.73% 284/804 |
-6.12% 804/850 |
11.99% 42/918 |
| 2018 | -38.90% 607/834 |
- - |
- - |
- - |
-12.72% 477/691 |
| 2017 | 12.83% 271/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.79% 204/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰国证有色金属行业指数(LOF)A VS. 长安沪深300非周期A(740101) |